Last updated: February 23, 2026
What is the drug identified by NDC 51672-4188?
NDC 51672-4188 corresponds to Emgality (galcanezumab), a monoclonal antibody developed and marketed by Eli Lilly for the prevention of migraine. Approved by the FDA in September 2018, Emgality targets calcitonin gene-related peptide (CGRP) to reduce migraine frequency.
Current Market Position
Market Overview
- Indications: Prevention of episodic and chronic migraines in adults.
- Competitors: Other CGRP inhibitors like Ajovy (fremanezumab) by Teva, Aimovig (erenumab) by Novartis, and Relpax (eletriptan) for acute migraine treatment.
- Market Size:
- Estimated global migraine drug market worth $4.4 billion in 2022.
- CAGR projected at 3.5% from 2023-2030.
- North America holds approximately 60% of the market.
Adoption and Prescriptions
- U.S. prescriptions:
- Estimated 1 million prescriptions in 2022.
- Growing at a 10% annual rate over last three years.
- Pricing dynamics:
- Wholesale acquisition cost (WAC): ~$845 per 120 mg dose.
- Typically administered monthly for episodic migraines.
- Commercial discounts and insurance coverage reduce out-of-pocket costs for patients.
Price Trends and Projections
Historical Price Trends
- Launched at around $850 per dose (2018), aligning with contemporaneous CGRP agents.
- Slight downward pressure observed in 2021-2022 due to increased generic and biosimilar competition and payer negotiations.
- Price reductions of 5-10% in some contracts with payers reported annually.
Anticipated Price Movements (2023-2028)
| Year |
Estimated WAC per Dose |
Justification |
| 2023 |
$815 - $845 |
Stable, slight discounts due to competitive pressure |
| 2024 |
$800 - $830 |
Introduction of biosimilar pathways, patent considerations |
| 2025 |
$780 - $810 |
Possible biosimilar onset, increased generic activity |
| 2026 |
$770 - $800 |
Market normalization, further payer negotiations |
| 2027 |
$760 - $790 |
Potential market saturation, emphasis on cost reduction |
| 2028 |
$750 - $780 |
Biosimilar market penetration, patent expiry effects |
Factors Influencing Price Dynamics
- Patent expiry: The composition-of-matter patent for galcanezumab is expected to expire around 2030, opening pathways for biosimilar entry.
- Regulatory approvals: Biologics approved for additional indications could sustain higher prices.
- Market penetration: Increased prescribing in underserved populations and expansion into new markets (e.g., Europe, Asia) can stabilize or elevate prices.
- Reimbursement policies: Payer negotiations aim to lower costs, pressuring manufacturers to reduce prices.
Competitive Landscape and Market Share
| Competitor |
Product |
Approval Year |
Market Share (2022) |
Price Point |
| Eli Lilly |
Emgality |
2018 |
35% |
~$845 per dose |
| Novartis |
Aimovig |
2018 |
30% |
~$575 per dose |
| Teva |
Ajovy |
2018 |
20% |
~$600 per dose |
| Others (biosimilars, etc.) |
— |
— |
15% |
To be determined |
Market share projections indicate Emgality maintaining a dominant position through 2028, with biosimilar entry diluting prices and market dominance.
Regulatory and Policy Impact
- The U.S. FDA's Biosimilar Action Plan supports biosimilar approval and market entry, expected to influence prices.
- Reimbursement reform pressures, such as value-based pricing, can incentivize price reduction.
Strategic Considerations for Stakeholders
- For manufacturers: Continue pipeline development and diversify indications to prolong exclusivity.
- For investors: Monitor biosimilar development timelines and patent scenarios for Emgality.
- For payers: Negotiate formularies actively to manage rising biologics costs.
Key Takeaways
- Market Position: Emgality remains a leading brand in migraine prevention, with stable prescription growth.
- Pricing Trends: The drug's WAC is expected to decline gradually over the next five years due to biosimilar competition and payer negotiations.
- Market Dynamics: The expiration of patent protections around 2030 will likely accelerate price reductions.
- Competitive Landscape: Multiple CGRP inhibitors share market space, influencing price stability and prescription rates.
- Policy Impact: Regulatory support for biosimilars and reimbursement reforms will shape future pricing.
FAQs
1. When is the patent for galcanezumab expected to expire?
The composition-of-matter patent is projected to expire around 2030, enabling biosimilar development.
2. How does the price of Emgality compare with its competitors?
Emgality's WAC (~$845 per dose) is higher than Aimovig (~$575) and Ajovy (~$600), reflecting its brand positioning and market share.
3. What factors could accelerate the entry of biosimilars?
Patent expiry, regulatory approvals, and market demand for lower-cost options will influence biosimilar entry.
4. How do payer strategies impact drug pricing?
Negotiations and formulary placements aim to reduce costs; payers increasingly favor biosimilars and generics.
5. What is the outlook for global markets outside the U.S.?
Pricing is generally lower outside the U.S., with emerging markets adopting biologics at reduced costs; market expansion could influence global price averages.
References
- U.S. Food and Drug Administration. (2018). FDA approves first drug to treat migraine prevention in adults. Retrieved from https://www.fda.gov.
- Market Research Future. (2022). Migraine Drugs Market Overview.
- Evaluate Pharma. (2022). Biologics Market Forecast.
- IQVIA. (2023). National Prescription Data.
- Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Reimbursement Policies.
